Fairvalue-Calculator Fairvalue-Calculator
EN DE

Abeona Therapeutics Inc (ABEO) Fair Value & Analysis

Healthcare · US · Market cap $325M

Price$5.62
Fair Value$12.57
Upside+123.7%
Quality95/100
Evidence: Medium Range $9.43 – $48.75

Fair value as of: Jun 25, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Abeona Therapeutics Inc (ABEO) currently trades at $5.62, while our model-based Fair Value estimate is $12.57 — implying the stock looks roughly 123.7% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.

About the company

Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was founded in 1974 and is headquartered in Cleveland, Ohio.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -38% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -28% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) -28% Alnylam Pharmaceuticals, Inc (ALNY) -63%

Frequently asked questions

Is Abeona Therapeutics Inc (ABEO) undervalued?
As of Jun 25, 2026, our model estimates a fair value of $12.57 versus a price of $5.62 — about +124% (undervalued). Model-based estimate, not financial advice.
What is the fair value of ABEO?
Our 21-model fair value for Abeona Therapeutics Inc is $12.57 (as of Jun 25, 2026), built from audited fundamentals. The current price is $5.62.
What is the quality score of ABEO?
Abeona Therapeutics Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.